HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing of tear volume, from the previous Phase III study. The top-line data for the Phase III VELOS-4 study is expected in the second half of 2025. ROCKVILLE, Md. and SEOUL, South Korea, May 3, 2024 /PRNew
May 3, 2024